

10/542313

JC17 Rec'd PCT/PTO 19 JUL 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
R. Guiles

Appln. No.: PCT/US04/002543

Group Art Unit: To be assigned

Filed: January 30, 2004

Examiner: To be assigned

For: NOVEL COMPOUNDS FOR THE TREATMENT OF SICKLE CELL DISEASE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

A copy of each reference on the PTO/SB/08 is provided herein.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.57(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be


Attorney Docket No. RG-2002-002
Application No. PCT/US04/002543

10/542313 Page 2
JC17 Rec'd PCT/PTO 15 JUL 2005

an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 21-0684. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Elizabeth Hart-Wells
Registration No. 50,931

University of Maryland, Baltimore
Telephone: (410) 706-2378
Facsimile: (410) 706-1066

Date: July 15, 2005.

Express mail: EV 600208537 US

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Application Number	PCT/US04/002543
Filing Date	
First Named Inventor	Ronald D. Guiles
Art Unit	
Examiner Name	
Attorney Docket Number	RG-2002-002

Sheet		of
-------	--	----

[illegible][illegible]Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known		
		Application Number	PCT/US04/002543	
		Filing Date		
		First Named Inventor	Ronald D. Guiles	
		Art Unit		
		Examiner Name		
Sheet		of	Attorney Docket Number	RG-2002-002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HOSSEINI M W. ET AL., "Multiple molecular recognition and catalysis. A multifunctional anion receptor bearing an anion binding site, an intercalating group and a catalytic	
		site for nucleotide binding and hydrolysis," Journal of the American Chemical Society, 1990, 3896-3904.	
		LOMOZIK, LECHOSLAW ET AL., "Copper(II) ions as a factor interfering in the interaction between bioligands in systems with adenosine and polyamines," Journal of Inorganic	
		Biochemistry, 1996, 63(3), 191-206.	
		FENNIRI, HITCHAM ET AL., "Molecular recognition of NADP(H) and ATP by macrocyclic polyamines bearing acridine groups," Helvetica Chimica Acta, 1997, 80(3), 786-803.	
		POL'SHAKOV, V I ET AL., "Interaction of the antitumor drugs prospidin and spiroboromin with nucleotides," Khimiko-Farmatsevticheskii Zhurnal, 1987, 21(5), 528-36.	
		POL'SHAKOV, V I ET AL., "Interaction of spirazidine, prospidine, and spirobromine with nucleic acid components," Khimiko-Farmatsevticheskii Zhurnal, 1989, 23(1), 10-16.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.